[
  {
    "ts": null,
    "headline": "More Drugs to Fight High Cholesterol Are Emerging",
    "summary": "The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades.  Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon.  Certain patients already can take a twice-yearly injection, sold by  Novartis  as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.",
    "url": "https://finnhub.io/api/news?id=fc4cccd5844bc150d3d155db22cb5e7fe5a1ea353738d6e1b38aabebe8281e65",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762640880,
      "headline": "More Drugs to Fight High Cholesterol Are Emerging",
      "id": 137384575,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "The lipid-reducing medicines, among the most widely prescribed drugs in the U.S., have been a mainstay of heart-disease prevention and treatment for decades.  Now some patients have other cholesterol-busting medicines available as options—and even more alternatives are on the horizon.  Certain patients already can take a twice-yearly injection, sold by  Novartis  as Leqvio, that uses an RNA-based technology, or a more frequent injection that targets a protein called PCSK9 that interferes with the body’s ability to clear the bad form of cholesterol.",
      "url": "https://finnhub.io/api/news?id=fc4cccd5844bc150d3d155db22cb5e7fe5a1ea353738d6e1b38aabebe8281e65"
    }
  },
  {
    "ts": null,
    "headline": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
    "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
    "url": "https://finnhub.io/api/news?id=38c2e182fbe918d935f5fdfe0b56e4be00f0be13755fb4651db912651cd4d2aa",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762630245,
      "headline": "Merck Takes On Amgen, Regeneron, Lowering Stubbornly High Cholesterol By 60%",
      "id": 137384576,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Merck said Saturday its new pill — a potential rival to Regeneron and Amgen — lowered stubbornly high cholesterol by almost 60%.",
      "url": "https://finnhub.io/api/news?id=38c2e182fbe918d935f5fdfe0b56e4be00f0be13755fb4651db912651cd4d2aa"
    }
  },
  {
    "ts": null,
    "headline": "AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL",
    "summary": "Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke, when added to statins or other low-density lipoprotein cholesterol (LDL-C)–lowering treatments. Repatha is the first and only PCSK9 inhibitor to demonstrate a significant reduction of",
    "url": "https://finnhub.io/api/news?id=796bff43ef7688d68b9c750f048ddeda2bd709b3b479883c63c4c1b2c3799f6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762614600,
      "headline": "AMGEN'S REPATHA® CUTS RISK OF FIRST MAJOR ADVERSE CARDIOVASCULAR EVENTS BY 25% IN LANDMARK PHASE 3 VESALIUS-CV TRIAL",
      "id": 137384594,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (NASDAQ:AMGN) today announced detailed results from the Phase 3 VESALIUS-CV clinical trial, which showed that Repatha® (evolocumab) achieved statistically significant and clinically meaningful reductions in major adverse cardiovascular events (MACE) in high-risk adults without a prior heart attack or stroke, when added to statins or other low-density lipoprotein cholesterol (LDL-C)–lowering treatments. Repatha is the first and only PCSK9 inhibitor to demonstrate a significant reduction of",
      "url": "https://finnhub.io/api/news?id=796bff43ef7688d68b9c750f048ddeda2bd709b3b479883c63c4c1b2c3799f6c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. Just Beat EPS By 128%: Here's What Analysts Think Will Happen Next",
    "summary": "Amgen Inc. ( NASDAQ:AMGN ) investors will be delighted, with the company turning in some strong numbers with its latest...",
    "url": "https://finnhub.io/api/news?id=3cc47ffb8566a6e481f5d845722e87f6db2ed1e5d7b1b3cf2be902e22c6b3bd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762605246,
      "headline": "Amgen Inc. Just Beat EPS By 128%: Here's What Analysts Think Will Happen Next",
      "id": 137378399,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. ( NASDAQ:AMGN ) investors will be delighted, with the company turning in some strong numbers with its latest...",
      "url": "https://finnhub.io/api/news?id=3cc47ffb8566a6e481f5d845722e87f6db2ed1e5d7b1b3cf2be902e22c6b3bd8"
    }
  },
  {
    "ts": null,
    "headline": "Jim Cramer on Amgen: “They Have A Lot of Good Medicines”",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said that the company needs to “broaden the portfolio,” as he remarked: “Look, I think Amgen needs to do something because they’ve gotta broaden the portfolio where they need to be able to tell a little bit better story about […]",
    "url": "https://finnhub.io/api/news?id=bc83673df731541261566574d11113430657790dd3c3fd2b6389cc88d74bc1dc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762574814,
      "headline": "Jim Cramer on Amgen: “They Have A Lot of Good Medicines”",
      "id": 137378400,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the stocks Jim Cramer recently shared thoughts on. Cramer said that the company needs to “broaden the portfolio,” as he remarked: “Look, I think Amgen needs to do something because they’ve gotta broaden the portfolio where they need to be able to tell a little bit better story about […]",
      "url": "https://finnhub.io/api/news?id=bc83673df731541261566574d11113430657790dd3c3fd2b6389cc88d74bc1dc"
    }
  },
  {
    "ts": null,
    "headline": "Amgen: Buy This Cheap Biotech Leader",
    "summary": "Amgen (AMGN) is a top biotech value pick with strong sales, robust R&D, and resilient growth. Read here for an analysis of AMGN stock.",
    "url": "https://finnhub.io/api/news?id=19b8b00efec1c3bca2134728f5aec86dbd4d8d14d9abe4153f833a19643b5245",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762560667,
      "headline": "Amgen: Buy This Cheap Biotech Leader",
      "id": 137376601,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1304930579/image_1304930579.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "Amgen (AMGN) is a top biotech value pick with strong sales, robust R&D, and resilient growth. Read here for an analysis of AMGN stock.",
      "url": "https://finnhub.io/api/news?id=19b8b00efec1c3bca2134728f5aec86dbd4d8d14d9abe4153f833a19643b5245"
    }
  }
]